Patent application number | Description | Published |
20100105900 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER - A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. | 04-29-2010 |
20100292302 | INDUCTION OF APOPTOSIS AND INHIBITION OF CELL PROLIFERATION THROUGH MODULATION OF CARNITINE PALMITOYLTRANSFERASE 1C ACTIVITY - This invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for treating tumors by inhibiting the activity of CPT1C. The methods and compositions can additionally include inhibition of glycolysis. | 11-18-2010 |
20110002923 | METHODS OF INHIBITING TUMOR GROWTH USING TTK ANTAGONISTS - The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject. | 01-06-2011 |
20110015174 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER - A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. | 01-20-2011 |
20110065702 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER - The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof. | 03-17-2011 |
20110112102 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST - The present invention relates to methods for treating cancer by administering a therapeutically effective amount of compound of formula (I), such as selective NPY5R antagonist MK-0557 (trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H), 1′-cyclohexane]-4′-carboxamide), or a pharmaceutically acceptable salt thereof, to a subject in need thereof The methods can further comprise administering a chemotherapeutic agent to the subject in need thereof. | 05-12-2011 |
20110243927 | METHODS OF INHIBITING TUMOR GROWTH USING BETA 5 INTEGRIN ANTAGONISTS - The present invention relates to methods for treating cancer by administering to a mammalian subject a therapeutically effective amount of a selective β | 10-06-2011 |
20110263598 | KINASE INHIBITORS AND METHOD OF TREATING CANCER - The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: | 10-27-2011 |
20120149686 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME - The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein. | 06-14-2012 |
20120264800 | KINASE INHIBITORS AND METHOD OF TREATING CANCER - The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: | 10-18-2012 |
20130123273 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR - Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present. | 05-16-2013 |
20140045822 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME - The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: | 02-13-2014 |
20140045838 | KINASE INHIBITORS AND METHOD OF TREATING CANCER - The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: | 02-13-2014 |
20140086938 | METHODS OF INHIBITING TUMOR GROWTH USING TTK ANTAGONISTS - The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject. | 03-27-2014 |
20150182504 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR - Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist. | 07-02-2015 |
Patent application number | Description | Published |
20090269811 | IL-1 RELATED POLYPEPTIDES - The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 10-29-2009 |
20090270595 | IL-1 RELATED POLYPEPTIDES - The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 10-29-2009 |
20090304701 | ANTIBODIES BINDING IL-1 RELATED POLYPEPTIDES - The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 12-10-2009 |
Patent application number | Description | Published |
20080312465 | INTERMEDIATE COMPOUNDS IN THE SYNTHESIS OF DRONABINOL - Dronabinol, the tetrahydrocannabinol compound which comprises the active constituent of marijuana and is pharmaceutically useful as an antiemetic, is prepared by a process involving reaction of cis-menth-1-ene-3,8-diol with olivetol to form 1,3-dihydroxy-2-[(1R,6R)-6-(2-hydroxyprop-2-yl)-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene; and cyclizing the 1,3-dihydroxy-2-[(1R,6R)-6-(2-hydroxypropr-2-yl)-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene so formed to obtain dronabinol. A novel synthesis of cis-menth-1-ene-3,8-diol is also provided. | 12-18-2008 |
20100063307 | PARICALCITOL PURIFICATION - Paricalcitol, a synthetic vitamin D analog, is purified to a purity greater than 99.7% by crystallization from solution in isopropyl acetate solvent, followed by filtration and vacuum drying. Isopropyl acetate appears to be unique among commonly available and pharmaceutically acceptable solvents in its ability to precipitate paricalcitol in this high purity, essentially free of isomers thereof. In addition, paricalcitol of purity of at least 99.9% has been shown to have exceptional storage stability. | 03-11-2010 |
20100063330 | PARICALCITOL PURIFICATION - Paricalcitol, a synthetic vitamin D analog, is purified to a purity greater than 99.7% by crystallization from solution in isopropyl acetate solvent, followed by filtration and vacuum drying. Isopropyl acetate appears to be unique among commonly available and pharmaceutically acceptable solvents in its ability to precipitate paricalcitol in this high purity, essentially free of isomers thereof. | 03-11-2010 |
20140323744 | PROCESS FOR PREPARATION OF (3R)-2,4-DI-LEAVING GROUP-3-METHYLBUT-1-ENE - The specification relates to compounds and process for the preparation of a compound of formula 7, | 10-30-2014 |
20150065733 | SYNTHETIC PROCESS FOR PREPARATION OF MACROCYCLIC C1-KETO ANALOGS OF HALICHONDRIN B AND INTERMEDIATES USEFUL THEREIN - Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R | 03-05-2015 |
Patent application number | Description | Published |
20090258996 | HYDROGENATION OF DIENE-BASED POLYMER LATEX - The present invention relates to a process for the selective hydrogenation of the carbon-carbon double bonds in a diene-based polymer latex using a water-soluble catalyst and simultaneously a water-insoluble co-catalyst. | 10-15-2009 |
20090270562 | HYDROGENATION OF DIENE-BASED POLYMERS - The present invention relates to a process for the selective hydrogenation of the carbon-carbon double bonds in diene-based polymers in bulk form by treatment of the polymer with hydrogen in the presence of a platinum group metal containing catalyst and in the absence of any organic solvent. | 10-29-2009 |
20090270563 | HYDROGENATION OF DIENE-BASED POLYMERS - The present invention relates to a process for the hydrogenation of the carbon-carbon double bonds in diene-based polymers in bulk form by treatment of said diene-based polymer with hydrogen in the presence of an iridium containing catalyst and in the absence of any organic solvent. | 10-29-2009 |
20090281248 | HYDROGENATION OF DIENE-BASED POLYMER LATEX - The present invention relates to a process for the hydrogenation of the carbon-carbon double bonds in a diene-based polymer latex in the absence of any organic solvent by a catalytically active system prepared in-situ based on a first main catalyst component and a secondary water-insoluble catalyst component. | 11-12-2009 |
20100093931 | PROCESS FOR THE CONTINUOUS HYDROGENATION OF CARBON-CARBON DOUBLE BONDS IN AN UNSATURATED POLYMER TO PRODUCE A HYDROGENATED POLYMER - Proposed is a process for the continuous hydrogenation of carbon-carbon double bonds in an unsaturated polymer to produce a hydrogenated polymer, said unsaturated polymer being based on a conjugated diolefin and at least one other copolymerizable monomer, in the presence of a homogeneous or heterogeneous catalyst, wherein said unsaturated polymer, hydrogen and said homogeneous or heterogeneous catalyst is passed through a multistage agitated reactor, comprising a cylindrical, elongated shell having closed ends and separated by baffles into a multiplicity of discrete chambers with access from one chamber to another through concentric circular openings, axially centered with said baffles and a continuous rotatable shaft extending concentric with said baffles within said shell with at least one impeller attached thereto positioned in each chamber, said continuous rotatable shaft and said circular openings providing annular openings and said hydrogenated polymer being withdrawn at the opposite end of the multistage agitated reactor at which the feed is introduced. | 04-15-2010 |
20110178231 | Nano-sized hydrogenated diene-based latex particles - The present invention relates to hydrogenated nano-sized diene-based latex particles, a method for their production and their use. | 07-21-2011 |
20110184120 | Nano-sized diene-based polymer latex particles - The present invention refers to diene-based unsaturated polymer latex particles having a particle size measured as d | 07-28-2011 |
20120270047 | NANO-SIZED DIENE-BASED POLYMER LATEX PARTICLES - The present invention refers to diene-based unsaturated polymer latex particles having a particle size measured as d | 10-25-2012 |
20120270996 | Nano-Sized Hydrogenated Diene-Based Latex Particles - The present invention relates to diene-based hydrogenated polymer latex particles having a particle size measured as d | 10-25-2012 |
20150183892 | HYDROGENATION OF A DIENE-BASED POLYMER LATEX - The present invention provides a novel process for selectively hydrogenating the carbon-carbon double bonds in diene-based polymers which are present in latex form, this means as a suspension of diene-based polymer particles in an aqueous medium, using a Ruthenium or Osmium-based complex catalyst without any organic solvent. | 07-02-2015 |
20150232584 | TANDEM METATHESIS AND HYDROGENATION OF DIENE-BASED POLYMERS IN LATEX - The present invention provides a novel process for subjecting a diene-based-polymer to a metathesis reaction in a first step and a selective hydrogenation of the carbon-carbon double bonds present in such diene-based polymers in a second step using a ruthenium or osmium based complex catalyst, wherein the diene-based polymer is present in latex form, this means as a suspension of diene-based polymer particles in an aqueous medium. | 08-20-2015 |
20150232585 | HYDROGENATION OF DIENE-BASED POLYMER LATEX IN THE PRESENCE OF AN IN SITU SYNTHESIZED CATALYST - A technique of improving the hydrogenation reaction of diene-based polymers, present in aqueous suspension, by in-situ synthesizing the catalyst in the presence of a specific aliphatic alcohol is disclosed. The process allows the selective hydrogenation of the carbon-carbon double bonds in the diene-based polymers with a high degree of hydrogenation and short reactions times. The improved process eliminates the complicated catalyst synthesis operations so far necessary. | 08-20-2015 |
Patent application number | Description | Published |
20090230930 | Adaptive Power Supply and Related Circuitry - A power supply configuration includes a monitor circuit to monitor an output voltage and output current of a power supply. The output voltage can be used to supply power to a dynamic load. The power supply varies a rate of changing an adaptive output voltage reference value that tracks the output voltage. Based on a comparison of the output voltage with respect to the adaptive output voltage reference voltage value, a controller associated with the power supply controls switching operation of the power supply to maintain the output voltage within a voltage range. For example, modifying the rate of changing the adaptive output voltage reference value over time depending on current operating conditions of the power supply changes a responsiveness and ability of the power supply to provide current to the dynamic load. | 09-17-2009 |
20110261593 | Power Converter for a Power Generator - Provided are methods, circuits, and systems for obtaining power from a power generator such as a photovoltaic cell or a fuel cell. The methods, circuits, and systems comprise converting substantially DC output power from the power generator into a high frequency AC voltage while rejecting or minimizing oscillations in the output power from the power generator; converting the high frequency AC voltage into a high frequency substantially sinusoidal voltage or current; and converting the high frequency substantially sinusoidal AC voltage or current into (i) a DC voltage or current, and (ii) a low frequency substantially sinusoidal AC voltage or current; wherein the high frequency substantially sinusoidal AC voltage or current is isolated from the DC voltage or current or the low frequency substantially sinusoidal AC voltage or current. | 10-27-2011 |
20150138841 | HIGH EFFICIENCY DC/DC CONVERTER AND CONTROLLER - Systems, methods, and devices for use in a DC/DC converter. A circuit uses a full-bridge power semiconductor subcircuit along with a high power transformer subcircuit, a diode bridge subcircuit, and a parallel capacitor to provide galvanic isolation and boost the voltage from a power source such as a photovoltaic panel. To ensure zero voltage switching for the power semiconductors, either a passive auxiliary subcircuit or an inductor coupled in parallel to a transformer in the transformer subcircuit may be used. A controller which derives its timing signals from the transformer primary current is used to control the timing of the power semiconductors in the circuit. The circuit and its controller allows for self-adjusting regardless of load and uses the entire switching cycle to be used for power transfer. | 05-21-2015 |
20150160676 | MULTI-INPUT PV INVERTER WITH INDEPENDENT MPPT AND MINIMUM ENERGY STORAGE - Systems, methods, and devices relating to the use of multiple DC power generation sources with DC/DC converters to thereby provide AC power suitable for provision to a power grid. Multiple DC power generation sources are each coupled to an input stage with a DC/DC converter. All the DC/DC converters in the multiple input stages are controlled by a single digital controller. Within the single digital controller are controller sub-blocks, each of which generates control signals for a specific DC/DC converter. Each controller sub-block provides multiple functions for improving the performance of the system as a whole. | 06-11-2015 |
20150163949 | INTEGRATED MICROINVERTER HOUSING FOR A PV AC MODULE - Systems and devices relating to an integrated housing for microinverters. The housing has a cavity for housing the circuitry of the microinverter. The housing is mountable on a back sheet of a PV module by way of the housing's top cover. An opening at the back of the housing accommodates DC contacts coming from the PV module while a void configured for an output port is also present in the housing. When mounted on the PV module, the housing is spaced apart from the module. | 06-11-2015 |
20150194909 | ZVS VOLTAGE SOURCE INVERTER - Systems and methods relating to zero voltage switching for inverters. A full bridge inverter is used in conjunction with a passive auxiliary circuit and an output filter. A control system controls the current by way of the auxiliary circuit and injects a high quality current to a power grid. The control system adjusts the duty ratio and switching frequency of the gate pulses applied to the power semiconductors in the full-bridge inverter. As well, the control system adjusts the phase shift between gate pulses for both the leading leg and lagging leg power semiconductors to control the current passing through the auxiliary circuit. | 07-09-2015 |
20150236617 | ZVS VOLTAGE SOURCE INVERTER WITH REDUCED OUTPUT CURRENT RIPPLE - Systems, methods, and devices relating to DC/AC converters. A circuit including a full bridge inverter is provided. One leg of power semiconductor subcircuits of the inverter is switched at line frequency while the other leg is soft switched at a higher frequency using an auxiliary circuit. A control system is used to calculate this higher optimal frequency. To minimize the output current ripple in the output filter, the output inductor is coupled to the auxiliary inductor in the auxiliary circuit. | 08-20-2015 |
20150326144 | DC-ELIMINATING CURRENT CONTROLLER FOR GRID-CONNECTED DC/AC CONVERTERS - Systems, methods, and devices which eliminate the DC current from the output of grid-connected inverters. A current controller is provided which interfaces with a grid-connected DC/AC inverter. The current controller uses a nonlinear adaptive filter which receives, as input, the output current of the inverter along with grid current frequency. The nonlinear adaptive filter estimates the DC value of the grid current and, in conjunction with an integrator, removes this DC current component. This is done by adjusting the duty cycle of the grid-connected inverter. | 11-12-2015 |
Patent application number | Description | Published |
20130071934 | METHOD AND SYSTEM FOR MEASUREMENT OF RESERVOIR FLUID PROPERTIES - A method and system that characterizes hydrogen sulfide in petroleum fluid employs a tool that includes a fluid analyzer for performing fluid analysis (including optical density (OD) for measuring carbon dioxide concentration) of a live oil sample, and a storage chamber for an analytical reagent fluidly coupled to a measurement chamber. An emulsion from fluid of the sample and the reagent is produced into the measurement chamber. The reagent changes color due to pH changes arising from chemical reactions between components of the sample and the reagent in the measurement chamber. The tool includes an optical sensor system that measures OD of a water phase of the emulsion at one or more determined wavelengths. The pH of the water phase is derived from such OD measurements. The pH of the water phase and the carbon dioxide concentration in the sample is used to calculate hydrogen sulfide concentration in the sample. | 03-21-2013 |
20140200810 | Methods For Reservoir Evaluation Employing Non-Equilibrium Compositional Gradients - A method for determining reservoir architecture using modeling of a non-equilibrium distribution of at least one analyte in reservoir fluids. The analyte(s) of the analysis preferably has (have) significant compositional variation in the reservoir. For example, the analyte can be a later charging single gas component (such as methane, carbon dioxide, or hydrogen sulfide) in a multi-component fluid system. In this case, the model can assume that the components of the early charge are in a stationary state or in equilibrium, whereas the later charge is in a state of non-equilibrium. The non-equilibrium distribution of the analyte(s) derived from the model is compared to the distribution of the analyte(s) derived from downhole or laboratory fluid analysis of reservoir fluid, and the architecture of the reservoir is determined based upon such comparison. | 07-17-2014 |
20150308264 | Downhole Real-Time Filtrate Contamination Monitoring - A method includes identifying linearly behaving data within obtained data associated with fluid obtained from a subterranean formation. Shrinkage factor is determined based on the linearly behaving data. A function relating GOR data of the obtained fluid with the determined shrinkage factor is determined. A first linear relationship between optical density (OD) data of the obtained fluid and the function is determined. A second linear relationship between density data of the obtained fluid and the function is determined. An oil-based mud (OBM) filtrate contamination property of OBM filtrate within the obtained fluid based on the first linear relationship is determined. A native formation property of native formation fluid within the obtained fluid based on the second linear relationship is determined. A volume fraction of OBM filtrate contamination within the obtained fluid based on the OBM filtrate contamination property and the native formation property is estimated. | 10-29-2015 |
Patent application number | Description | Published |
20110069715 | ACCELERATING DATA COMMUNICATION USING TUNNELS - Methods and systems are provided for increasing application performance and accelerating data communications in a WAN environment. According to one embodiment, packets are received at a flow classification module operating at the Internet Protocol (IP) layer of a first wide area network (WAN) acceleration device via a shared connection-oriented tunnel, which is operable to convey application layer data for connection-oriented applications between WAN acceleration devices. Packets that are classified as being associated with an existing connection-oriented flow are passed to a WAN socket operating at the transport layer. Based on the application protocol, the packets are passed to an application handler of multiple application handlers operating at the application layer each of which implements one or more application acceleration techniques for a particular poorly behaved WAN protocol. The existing connection-oriented flow is securely accelerated by performing one or more application acceleration techniques and applying one or more security functions. | 03-24-2011 |
20130311671 | ACCELERATING DATA COMMUNICATION USING TUNNELS - Methods and systems are provided for increasing application performance and accelerating data communications in a WAN environment. According to one embodiment, packets are received at a flow classification module operating at the Internet Protocol (IP) layer of a first wide area network (WAN) acceleration device via a private tunnel, which is operable to convey application layer data for connection-oriented applications between WAN acceleration devices. Packets that are classified as being associated with an existing connection-oriented flow are passed to a WAN socket operating at the transport layer. Based on the application protocol, the packets are passed to an application handler of multiple application handlers operating at the application layer each of which implements one or more application acceleration techniques for a particular application layer protocol known to behave poorly within a WAN environment. The existing connection-oriented flow is securely accelerated by performing one or more application acceleration techniques and applying one or more security functions. | 11-21-2013 |
20150281277 | NETWORK POLICY ASSIGNMENT BASED ON USER REPUTATION SCORE - A network controller device, systems, and methods thereof are described herein for enabling a mechanism of assigning network policies to one or more users based on their respective client reputation (CR) scores. CR scores indicate a measure of the level and kind of network activity that an internal resource does with external resources. Based on the evaluation of the CR score for a given user, system of the present invention can be configured to implement an appropriate policy on the user that controls the manner in which the user interacts within and outside the network. Proposed system includes multiple virtual local area networks (VLANs), wherein each VLAN is configured with a defined policy such that once the CR score for a given user has been evaluated, the user can be put on an appropriate VLAN based on the evaluation and the intended policy that the system wants the user to follow. | 10-01-2015 |
20150334088 | ACCELERATING DATA COMMUNICATION USING TUNNELS - Methods and systems are provided for increasing application performance and accelerating data communications in a WAN environment. According to one embodiment, packets are received at a flow classification module operating at the Internet Protocol (IP) layer of a first wide area network (WAN) acceleration device via a private tunnel, which is operable to convey application layer data for connection-oriented applications between WAN acceleration devices. The packets are passed to a WAN socket operating at the transport layer. Based on the application protocol, the packets are passed to an application handler of multiple application handlers operating at the application layer each of which implements one or more application acceleration techniques for a particular application layer protocol known to behave poorly within a WAN environment. The existing connection-oriented flow is securely accelerated by performing one or more application acceleration techniques and applying one or more security functions. | 11-19-2015 |